In an eight‑month‑old infant who is post‑bone‑marrow transplantation, what are the possible causes of a recurrent pericardial effusion?

Recurrent Pericardial Effusion in an 8-Month-Old Post-BMT Infant

In an 8-month-old post-bone marrow transplant patient with recurrent pericardial effusion, the most likely causes are calcineurin inhibitor (CNI) toxicity, viral reactivation (particularly EBV and CMV), graft-versus-host disease (GVHD), and transplant-associated thrombotic microangiopathy (Ta-TMA).

Primary Etiologies in Post-BMT Pediatric Patients

Calcineurin Inhibitor Toxicity (Most Common Treatable Cause)

• Young age is the strongest predictor for post-HSCT pericardial effusion, with each year decrease in age increasing risk (HR 0.66 per year) 1
• At 8 months old, this infant is at particularly high risk
• CNI toxicity (typically tacrolimus) appears to be the primary reversible cause 1
• Critical point: Discontinuation of CNIs is the only consistently effective treatment, more so than diuretics or increased immunosuppression 1
• However, recent data suggests that CNI continuation with conservative or surgical management may be feasible without triggering GVHD flares 2

Viral Reactivation (Highly Prevalent)

• DNA viruses are detected in 78% of pericardial fluid samples from post-umbilical cord blood transplant patients 3
• Epstein-Barr virus (EBV) is most common, followed by CMV 3, 4
• In early-onset effusions (<100 days post-transplant), viral presence is often systemic and secondary to severe inflammation 3
• In late-onset cases, localized viral reactivation within the pericardium may be the primary driver 3
• 87% of patients with effusions requiring intervention had recent treatment for viral reactivation 5
• CMV disease is frequently associated with multiple serosal effusions in GVHD patients 6

Graft-Versus-Host Disease

• GVHD grade is a significant risk factor for pericardial effusion 4
• Unexplained multiple serosal effusions (involving pleural, pericardial, or peritoneal cavities) occur exclusively in allogeneic transplant recipients with acute or chronic GVHD 6
• These effusions typically occur after engraftment, with 6 of 7 cases before day 100 6
• Often presents as part of severe acute or chronic GVHD, frequently in association with CMV disease 6

Transplant-Associated Thrombotic Microangiopathy (Ta-TMA)

• Ta-TMA is highly associated with pericardial effusions and carries increased mortality 5
• This represents a critical diagnosis that must be actively excluded

Conditioning Regimen Toxicity

• 87% of patients with effusions requiring intervention received cyclophosphamide as part of their preparative regimen 5
• Myeloablative conditioning regimens show higher rates of effusion, though not statistically significant 5
• Cyclophosphamide exposure is a significant risk factor 5

Other Considerations

• Hepatic veno-occlusive disease (HVOD) is a risk factor 4
• Pulmonary infection 4
• Abnormal pre-HSCT electrocardiogram 4
• Higher left ventricle end-diastolic diameter z-score correlates with effusion duration 5

Diagnostic Approach

Immediate Assessment

Per ESC guidelines, perform 7:

• Transthoracic echocardiography (Class I recommendation) to assess size, hemodynamic significance, and signs of tamponade
• Markers of inflammation (CRP, ESR) to distinguish inflammatory from non-inflammatory causes
• Chest X-ray for pleuropulmonary involvement
• ECG for pericarditis features

High-Risk Features Requiring Pericardiocentesis

Pericardiocentesis is indicated for 7:

• Cardiac tamponade
• Large effusions (≥2 cm or >20 mm diastolic echo-free space)
• Suspected bacterial or neoplastic etiology
• Symptomatic moderate-to-large effusions not responsive to medical therapy

Pericardial Fluid Analysis

When pericardiocentesis is performed, send fluid for 7, 3:

• Multiplex PCR for DNA viruses (EBV, CMV, HHV-6, adenovirus)
• Bacterial cultures (aerobic, anaerobic, mycobacterial)
• Cell count and cytology
• Chemistry (protein, LDH)

Additional Workup for Post-BMT Context

• Screen for Ta-TMA: LDH, haptoglobin, schistocytes, complement levels
• Assess for GVHD: Clinical examination for skin, GI, liver involvement
• Viral surveillance: EBV and CMV PCR in blood
• Review current medications: Document CNI levels and duration of exposure
• Evaluate for HVOD: Liver function tests, bilirubin, hepatic ultrasound with Doppler

Management Algorithm

For Recurrent Effusions

1. If CNI-associated (most likely in this age group):

   • Traditional approach: Discontinue CNI 1
   • Alternative approach: Continue CNI with close monitoring if GVHD risk is high 2
   • Consider pericardiocentesis with drainage for 3-5 days 8

2. If viral reactivation identified:

   • Treat specific viral pathogen (ganciclovir for CMV, rituximab for EBV)
   • Consider that localized pericardial viral reactivation may require different management than systemic viremia 3

3. If GVHD-associated:

   • Optimize GVHD treatment
   • Multiple serosal effusions suggest severe GVHD requiring aggressive immunosuppression 6

4. If refractory or recurrent despite medical management:

   • Surgical pericardial window if drainage remains high 6-7 days after pericardiocentesis 8
   • Pericardiotomy has lower recurrence rates than percutaneous pericardiocentesis 8

Critical Pitfalls

• Do not rely on anti-inflammatory therapy alone (NSAIDs, colchicine, corticosteroids) for isolated effusions without inflammation—they are generally ineffective 7
• Do not assume idiopathic etiology in post-BMT patients—systematic evaluation for specific causes is essential 7
• Monitor closely: 93% of post-HSCT pericardial effusions occur within 100 days, with median onset at 25 days 4
• Recognize that pericardial effusion negatively impacts overall survival after HSCT 4

Prognosis

• Most effusions resolve with appropriate treatment 4, 1
• Pericardial effusion itself did not impact survival in one pediatric series when appropriately managed 1
• However, other studies show significant negative effect on overall survival 4
• Mortality risk is highest with Ta-TMA association and cardiac tamponade 5, 4